Clinical Trials
47 trialsEfficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Tislelizumab and Regorafenib as First-Line Therapy for Advanced Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
EREMISS
Centre Oscar Lambret
REGO-SARC
Centre Oscar Lambret
DREAM
First Affiliated Hospital, Sun Yat-Sen University
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Memorial Sloan Kettering Cancer Center
Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma
Case Comprehensive Cancer Center
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Bayer
A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors
Bayer
a-MANTRA
Gruppo Oncologico Italiano di Ricerca Clinica
REPROGRAM-01
Centre Hospitalier Universitaire de Besancon
ROCKET
EpicentRx, Inc.
Regorafenib in Metastatic Colorectal Cancer
University of Rochester
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
Bayer
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
The University of Texas Health Science Center at San Antonio
Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
SCRI Development Innovations, LLC
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations
SCRI Development Innovations, LLC
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Sarcoma Alliance for Research through Collaboration
REGOVAR
ARCAGY/ GINECO GROUP
Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer
Stanford University
Study on the Effectiveness and Safety of the Combination of the Two Drugs Regorafenib and Nivolumab in Patients With Colorectal Cancer (Cancer of the Colon or Rectum Classified as Proficient Mismatch Repair and Microsatellite Stable)
Bayer
REGISTRI
Grupo Espanol de Investigacion en Sarcomas
RENOBATE
Asan Medical Center
RESOUND
Istituto Clinico Humanitas
REGOMA
Istituto Oncologico Veneto IRCCS
Use of Regorafenib in Recurrent Epithelial Ovarian Cancer
National Cancer Centre, Singapore
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Northwestern University
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
Wake Forest University Health Sciences
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
University of Southern California
Single Agent Regorafenib in Refractory Advanced Biliary Cancers
H. Lee Moffitt Cancer Center and Research Institute
A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC
Bayer
Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer
UNC Lineberger Comprehensive Cancer Center
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Dana-Farber Cancer Institute
Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)
University of Alabama at Birmingham
FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer
Memorial Sloan Kettering Cancer Center
RE-ARRANGE
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Asan Medical Center
PARICCA
British Columbia Cancer Agency
RegARd-C
Jules Bordet Institute
ZnCORRECT
Chang Gung Memorial Hospital
Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation
Chang Gung Memorial Hospital
TEXCAN
GERCOR - Multidisciplinary Oncology Cooperative Group
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
University of Pittsburgh
Regorafenib in Subjects With Antiangiogenic-naive and Chemotherapy-refractory Advanced Colorectal Cancer
Bayer
REFRAME
Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
First Line Treatment of Metastatic Colorectal Cancer With mFOLFOX6 in Combination With Regorafenib
Bayer
Safety Study of BAY73-4506 in Patients With Hepatocellular Carcinoma
Bayer